Document is current
Any future updates will be listed below
-
Authors
Meinert, Christoph https://orcid.org/0000-0002-7036-4067
Weekes, Angus https://orcid.org/0000-0002-9844-5774
Chang, Chun-Wei
Schrobback, Karsten https://orcid.org/0000-0002-9312-7275
Gelmi, Amy
Stevens, Molly M. https://orcid.org/0000-0002-7335-266X
Hutmacher, Dietmar W. https://orcid.org/0000-0001-5678-2134
Klein, Travis J. https://orcid.org/0000-0002-6669-7766
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (660757)
Wellcome Trust (098411/Z/12/Z)
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 14 March 2025
First Online: 27 March 2025
Competing interests
: C. Meinert, T.J. Klein, and D.W. Hutmacher are co-founders and shareholders of Gelomics Pty Ltd. C. Meinert is also the Chief Executive Officer and an Executive Director of Gelomics Pty Ltd. T.J. Klein, D.W. Hutmacher and M.M. Stevens serve on the Scientific Advisory Board of Gelomics Pty Ltd. M.M. Stevens has invested in, consults for (or is on scientific advisory boards or boards of directors) and conducts sponsored research funded by companies related to the biomaterials field; has filed patent applications related to biomaterials; and has co-founded companies in the biomaterials field.
: Ethical approval was granted for this research from the Queensland University of Technology Human Research Ethics Committee (EC00171) and the Prince Charles Hospital Human Research Ethics Committee (EC00168) (both Brisbane, Australia), and written informed consent was obtained from donors for use of tissue samples. All experiments were performed in accordance with the National Health and Medical Research Council (NHMRC) guidelines.
